<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553240</url>
  </required_header>
  <id_info>
    <org_study_id>5438</org_study_id>
    <nct_id>NCT01553240</nct_id>
  </id_info>
  <brief_title>Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies</brief_title>
  <official_title>Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses functional brain imaging and noninvasive brain stimulation techniques to&#xD;
      study the brain basis of developmental disorders like Autism Spectrum Disorder and Asperger&#xD;
      Disorder. Functional magnetic resonance imaging (fMRI) and recently approved FDA treatment of&#xD;
      depression, Transcranial magnetic stimulation (TMS) will be used to study the neurocircuitry&#xD;
      of certain symptom clusters in developmental disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to study areas of the brain that may have something to do&#xD;
      with repetitive movements (things that people do over and over again) and difficulty&#xD;
      communicating with other people (problems with talking to, understanding, or just being in a&#xD;
      relationships with other people). The investigators are trying to find out why these brain&#xD;
      areas are working differently in people with developmental disorders, such as Autism and how&#xD;
      the investigators can one day improve them with new brain stimulation techniques.&#xD;
&#xD;
      The investigators will do screening to make sure that you are eligible for the study. After&#xD;
      screening, the investigators will do functional MRI. In this procedure the subject or the&#xD;
      control will be looking at videos developed to understand their social communication and&#xD;
      language skills. The investigators will be able to understand differences of brain activation&#xD;
      between patients and control. The investigators will also use TMS to identify the difference&#xD;
      of motor excitability between patients and healthy control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator (Dr. Sporn) left the sponsoring institution.&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repetitive Behavior Scale-revised</measure>
    <time_frame>during screening</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vineland Maladaptive Behavior Scale</measure>
    <time_frame>during screening</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Asperger Disorder</condition>
  <condition>Pervasive Developmental Disorder</condition>
  <arm_group>
    <arm_group_label>TMS and fMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS and functional MRI (Magstim)</intervention_name>
    <description>single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
    <arm_group_label>TMS and fMRI</arm_group_label>
    <other_name>Magstim, Magstim 200, BISTIM Module</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  for Healthy volunteer:&#xD;
&#xD;
               -  no current psychiatric disorder meeting Axis 1 DSM-4 criteria.&#xD;
&#xD;
               -  English speaking,&#xD;
&#xD;
               -  verbal and full scale IQ &gt; 65,&#xD;
&#xD;
               -  capacity to give consent and signed HIPPA authorization.&#xD;
&#xD;
          -  for Autism Spectrum Disorders:&#xD;
&#xD;
               -  diagnosed with Autism, Asperger or Pervasive Developmental Disorder not otherwise&#xD;
                  specified,&#xD;
&#xD;
               -  English speaking,&#xD;
&#xD;
               -  capacity to give consent and verbal and full scale IQ &gt; 65,&#xD;
&#xD;
               -  signed HIPPA authorization,&#xD;
&#xD;
               -  participants currently taking psychotropic medications must be at the same stable&#xD;
                  doses and be willing to continue at the same dose through out the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  for Healthy control and ASD:&#xD;
&#xD;
               -  women of child bearing potential not using birth control pills or breast feeding,&#xD;
&#xD;
               -  h/o bipolar disorder (lifetime),&#xD;
&#xD;
               -  any psychotic disorder( lifetime),&#xD;
&#xD;
               -  history of major depressive disorder or of substance abuse or dependence within&#xD;
                  the past year,&#xD;
&#xD;
               -  verbal or full scale IQ less than or equal to 65,&#xD;
&#xD;
               -  intracranial implants,&#xD;
&#xD;
               -  metallic implants,&#xD;
&#xD;
               -  shrapnel in the body,&#xD;
&#xD;
               -  metallic braces,&#xD;
&#xD;
               -  cardiac pacemakers or&#xD;
&#xD;
               -  vagus nerve stimulation device,&#xD;
&#xD;
               -  claustrophobia,&#xD;
&#xD;
               -  prior dx of seizure,&#xD;
&#xD;
               -  increased intracranial pressure or history of significant head trauma with loss&#xD;
                  of consciousness for at least 5 minutes&#xD;
&#xD;
               -  current significant laboratory abnormality,&#xD;
&#xD;
               -  neurological disorder including but not limited to space occupying brain lesion,&#xD;
&#xD;
               -  any history of seizures,&#xD;
&#xD;
               -  history of cerebrovascular accidents,&#xD;
&#xD;
               -  fainting,&#xD;
&#xD;
               -  cerebral aneurysm,&#xD;
&#xD;
               -  dementia,&#xD;
&#xD;
               -  huntington,&#xD;
&#xD;
               -  chorea,&#xD;
&#xD;
               -  multiple sclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Sporn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYPI, Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Lisanby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYPI, Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York state Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000 Jun;30(3):237-43.</citation>
    <PMID>11055459</PMID>
  </results_reference>
  <results_reference>
    <citation>Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001 Feb;31(1):5-17. Erratum in: J Autism Dev Disord 2001 Dec;31(6):603.</citation>
    <PMID>11439754</PMID>
  </results_reference>
  <results_reference>
    <citation>Roid, G.H. Stanford Binet Intelligence Scles, Fifth Edition ( Riverside Publishing, Itasca, IL, 2003)</citation>
  </results_reference>
  <results_reference>
    <citation>Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct;24(5):659-85.</citation>
    <PMID>7814313</PMID>
  </results_reference>
  <results_reference>
    <citation>Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000 Jun;30(3):205-23.</citation>
    <PMID>11055457</PMID>
  </results_reference>
  <results_reference>
    <citation>APA. Diagnostic and Statistical Manual of Mental States Disorders. 4th ed. DSM-4-R( American Psychiatric Association, Washington, DC,2000)</citation>
  </results_reference>
  <results_reference>
    <citation>Sparrow, S., Cicchetti, D. &amp; Balla,D. The Vineland-2 Adaptive Behavior Scales( Survey Interview Form) ( American Guidance Service, Circle Pines, MN, 2005)</citation>
  </results_reference>
  <results_reference>
    <citation>Constantino, J.N. The Social responsiveness Scale. ( Western psychological Services, Los Angeles, 2002)</citation>
  </results_reference>
  <results_reference>
    <citation>Baron-Cohen S, Jolliffe T, Mortimore C, Robertson M. Another advanced test of theory of mind: evidence from very high functioning adults with autism or asperger syndrome. J Child Psychol Psychiatry. 1997 Oct;38(7):813-22.</citation>
    <PMID>9363580</PMID>
  </results_reference>
  <results_reference>
    <citation>Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The &quot;Reading the Mind in the Eyes&quot; Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001 Feb;42(2):241-51.</citation>
    <PMID>11280420</PMID>
  </results_reference>
  <results_reference>
    <citation>Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16.</citation>
    <PMID>9474057</PMID>
  </results_reference>
  <results_reference>
    <citation>Wassermann EM, Grafman J, Berry C, Hollnagel C, Wild K, Clark K, Hallett M. Use and safety of a new repetitive transcranial magnetic stimulator. Electroencephalogr Clin Neurophysiol. 1996 Oct;101(5):412-7.</citation>
    <PMID>8913194</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>functional MRI</keyword>
  <keyword>Supplementary motor cortex</keyword>
  <keyword>Right Temporoparietal junction( RTPJ)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
    <mesh_term>Asperger Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TMS and fMRI</title>
          <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)&#xD;
TMS and functional MRI (Magstim): single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
      <group_list>
        <group group_id="B1">
          <title>TMS and fMRI</title>
          <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)&#xD;
TMS and functional MRI (Magstim): single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Gender</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Repetitive Behavior Scale-revised</title>
        <time_frame>during screening</time_frame>
        <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
        <group_list>
          <group group_id="O1">
            <title>TMS and fMRI</title>
            <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)&#xD;
TMS and functional MRI (Magstim): single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
          </group>
        </group_list>
        <measure>
          <title>Repetitive Behavior Scale-revised</title>
          <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vineland Maladaptive Behavior Scale</title>
        <time_frame>during screening</time_frame>
        <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
        <group_list>
          <group group_id="O1">
            <title>TMS and fMRI</title>
            <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)&#xD;
TMS and functional MRI (Magstim): single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
          </group>
        </group_list>
        <measure>
          <title>Vineland Maladaptive Behavior Scale</title>
          <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>TMS and fMRI</title>
          <description>functional MRI&#xD;
single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)&#xD;
TMS and functional MRI (Magstim): single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Sherman</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>(646) 774-7158</phone>
      <email>lsherma@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

